Cargando…

Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?

SIMPLE SUMMARY: The TCR is the T cell antigen receptor, and it is responsible of the T cell activation, through the HLA-antigen complex recognition. Studying the TCR repertoire in patients with cancer can help to better understand the anti-tumoural responses and it has been suggested to have predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Aran, Andrea, Garrigós, Laia, Curigliano, Giuseppe, Cortés, Javier, Martí, Mercè
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996954/
https://www.ncbi.nlm.nih.gov/pubmed/35406543
http://dx.doi.org/10.3390/cancers14071771
_version_ 1784684593345986560
author Aran, Andrea
Garrigós, Laia
Curigliano, Giuseppe
Cortés, Javier
Martí, Mercè
author_facet Aran, Andrea
Garrigós, Laia
Curigliano, Giuseppe
Cortés, Javier
Martí, Mercè
author_sort Aran, Andrea
collection PubMed
description SIMPLE SUMMARY: The TCR is the T cell antigen receptor, and it is responsible of the T cell activation, through the HLA-antigen complex recognition. Studying the TCR repertoire in patients with cancer can help to better understand the anti-tumoural responses and it has been suggested to have predictive and or/prognostic values, both for the disease and in response to treatments. The aim of this review is to summarize TCR repertoire studies performed in patients with cancer found in the literature, thoroughly analyse the different factors that can be involved in shaping the TCR repertoire, and draw the current conclusions in this field, especially focusing on whether the TCR diversity—or its opposite, the clonality—can be used as predictors or prognostic biomarkers of the disease. ABSTRACT: T cells play a vital role in the anti-tumoural response, and the presence of tumour-infiltrating lymphocytes has shown to be directly correlated with a good prognosis in several cancer types. Nevertheless, some patients presenting tumour-infiltrating lymphocytes do not have favourable outcomes. The TCR determines the specificities of T cells, so the analysis of the TCR repertoire has been recently considered to be a potential biomarker for patients’ progression and response to therapies with immune checkpoint inhibitors. The TCR repertoire is one of the multiple elements comprising the immune system and is conditioned by several factors, including tissue type, tumour mutational burden, and patients’ immunogenetics. Its study is crucial to understanding the anti-tumoural response, how to beneficially modulate the immune response with current or new treatments, and how to better predict the prognosis. Here, we present a critical review including essential studies on TCR repertoire conducted in patients with cancer with the aim to draw the current conclusions and try to elucidate whether it is better to encounter higher clonality with few TCRs at higher frequencies, or higher diversity with many different TCRs at lower frequencies.
format Online
Article
Text
id pubmed-8996954
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89969542022-04-12 Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality? Aran, Andrea Garrigós, Laia Curigliano, Giuseppe Cortés, Javier Martí, Mercè Cancers (Basel) Review SIMPLE SUMMARY: The TCR is the T cell antigen receptor, and it is responsible of the T cell activation, through the HLA-antigen complex recognition. Studying the TCR repertoire in patients with cancer can help to better understand the anti-tumoural responses and it has been suggested to have predictive and or/prognostic values, both for the disease and in response to treatments. The aim of this review is to summarize TCR repertoire studies performed in patients with cancer found in the literature, thoroughly analyse the different factors that can be involved in shaping the TCR repertoire, and draw the current conclusions in this field, especially focusing on whether the TCR diversity—or its opposite, the clonality—can be used as predictors or prognostic biomarkers of the disease. ABSTRACT: T cells play a vital role in the anti-tumoural response, and the presence of tumour-infiltrating lymphocytes has shown to be directly correlated with a good prognosis in several cancer types. Nevertheless, some patients presenting tumour-infiltrating lymphocytes do not have favourable outcomes. The TCR determines the specificities of T cells, so the analysis of the TCR repertoire has been recently considered to be a potential biomarker for patients’ progression and response to therapies with immune checkpoint inhibitors. The TCR repertoire is one of the multiple elements comprising the immune system and is conditioned by several factors, including tissue type, tumour mutational burden, and patients’ immunogenetics. Its study is crucial to understanding the anti-tumoural response, how to beneficially modulate the immune response with current or new treatments, and how to better predict the prognosis. Here, we present a critical review including essential studies on TCR repertoire conducted in patients with cancer with the aim to draw the current conclusions and try to elucidate whether it is better to encounter higher clonality with few TCRs at higher frequencies, or higher diversity with many different TCRs at lower frequencies. MDPI 2022-03-31 /pmc/articles/PMC8996954/ /pubmed/35406543 http://dx.doi.org/10.3390/cancers14071771 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Aran, Andrea
Garrigós, Laia
Curigliano, Giuseppe
Cortés, Javier
Martí, Mercè
Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
title Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
title_full Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
title_fullStr Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
title_full_unstemmed Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
title_short Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
title_sort evaluation of the tcr repertoire as a predictive and prognostic biomarker in cancer: diversity or clonality?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996954/
https://www.ncbi.nlm.nih.gov/pubmed/35406543
http://dx.doi.org/10.3390/cancers14071771
work_keys_str_mv AT aranandrea evaluationofthetcrrepertoireasapredictiveandprognosticbiomarkerincancerdiversityorclonality
AT garrigoslaia evaluationofthetcrrepertoireasapredictiveandprognosticbiomarkerincancerdiversityorclonality
AT curiglianogiuseppe evaluationofthetcrrepertoireasapredictiveandprognosticbiomarkerincancerdiversityorclonality
AT cortesjavier evaluationofthetcrrepertoireasapredictiveandprognosticbiomarkerincancerdiversityorclonality
AT martimerce evaluationofthetcrrepertoireasapredictiveandprognosticbiomarkerincancerdiversityorclonality